Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dechra Pharmaceuticals PLC Director's Dealing 2014

Mar 5, 2014

4797_dirs_2014-03-05_50b73e8c-f99c-4df5-b5d5-2fe9a505cd42.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6101B

Dechra Pharmaceuticals PLC

05 March 2014

5 March 2014

Dechra® Pharmaceuticals PLC

("Dechra" or "the Company")

Director / PDMR shareholding

Dechra Pharmaceuticals PLC has been notified that on 5 March 2014 Zoe Goulding, a PDMR of the Company, exercised 958 options over ordinary shares in the Company, granted to her on 13 December 2010 pursuant to the SAYE Scheme at an exercise price of £3.7564 each.  

Following this acquisition, Zoe Goulding's beneficial interest in the Company is 12,891 shares (0.015% of the current issued share capital).

For further information, please contact:

Melanie Hall, Assistant Company Secretary          

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Its expertise is in the development, manufacturing and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSQKPDBQBKDKNK